Australia Peptide Drug Conjugates Market Size & Outlook
Australia peptide drug conjugates market, 2018-2030 (US$M)
Related Markets
Australia peptide drug conjugates market highlights
- The Australia peptide drug conjugates market generated a revenue of USD 29.4 million in 2024 and is expected to reach USD 181.8 million by 2030.
- The Australia market is expected to grow at a CAGR of 26.1% from 2025 to 2030.
- In terms of segment, therapeutics was the largest revenue generating type in 2024.
- Therapeutics is the most lucrative type segment registering the fastest growth during the forecast period.
Peptide drug conjugates market data book summary
| Market revenue in 2024 | USD 29.4 million |
| Market revenue in 2030 | USD 181.8 million |
| Growth rate | 26.1% (CAGR from 2025 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Therapeutics |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Therapeutics, Diagnostics |
| Key market players worldwide | Novartis AG ADR, Oncopeptides AB, Bicycle Therapeutics PLC ADR, AstraZeneca PLC, Theratechnologies Inc, Cybrexa Therapeutics, AngioChem, Soricimed |
Other key industry trends
- In terms of revenue, Australia accounted for 0.8% of the global peptide drug conjugates market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan peptide drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 545.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Peptide Drug Conjugates Market Scope
Peptide Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia peptide drug conjugates market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peptide drug conjugates market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 117.01% in 2024. Horizon Databook has segmented the Australia peptide drug conjugates market based on therapeutics, diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
Supportive government initiatives are among the key factors driving the Australia peptide drug conjugates market. For instance, the ARC Centre of Excellence for Innovations in Peptide and Protein Science is a research initiative harnessing the characteristic Australian environment.
Their focus involves the discovery and evaluation of novel proteins and peptides derived from native Australian flora & fauna. These compounds hold the potential to be applied in novel ways within the domains of healthcare, agriculture, and industry.
The favorable regulatory framework and high demand for peptide based drugs in the country are likely to boost market expansion. Furthermore, the high prevalence of target diseases in the country makes it important for key players to formulate and manufacture newer drugs that are efficient & can help in reducing the burden of infection in the country.
Reasons to subscribe to Australia peptide drug conjugates market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia peptide drug conjugates market databook
-
Our clientele includes a mix of peptide drug conjugates market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia peptide drug conjugates market , including forecasts for subscribers. This country databook contains high-level insights into Australia peptide drug conjugates market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia peptide drug conjugates market size, by type, 2018-2030 (US$M)
Australia Peptide Drug Conjugates Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
